Personal Screening PLC
13 March 2006

13 March 2006



                     Personal Screening plc: Product Launch

Unique test for the hidden sexually transmitted disease Chlamydia


Personal Screening plc ("the Company"), the recently floated Aim listed company,
is pleased to announce the launch of a new instant result self test screening
kit for the sexually transmitted disease Chlamydia.


This is the second test for Chlamydia to be brought to market by the Company. 
The Company's first Chlamydia test was approved by the MHRA (Medical and Health
product Regulatory Agency) for over the counter sales in 2005.  This test
requires a urine sample to be taken and sent for analysis in a laboratory.  The
retail price point is #40.

The new test, which can only be used by women, comes with a number of important
advantages.  It gives an instant result, is very discrete and has a retail price
point of just #20.

The Company has signed an exclusive supply agreement with Surescreen Diagnostics
Limited, who together with the Company have completed the CE/IVD European
approval procedure.  The new self test kit is now in production and will be
available for sale through pharmacies by the end of the month.


Chlamydia is now the most common sexually transmitted disease in the UK.  It
often shows no symptoms and can be passed on by people who do not know they are
infected.  If left untreated the infection can spread to other parts of the body
causing damage and serious long-term health problems.  In women, chlamydia can
cause pelvic inflammatory disease and can lead to ectopic pregnancy, blocked
fallopian tubes, long-term pelvic pain, infertility, early miscarriage or
premature birth.

Between 1991 and 2001 the number of sexually transmitted infections in the UK
doubled to more than 1.3m reported cases a year.

Clamydia is recognised as the most rapidly growing STD with an increase in
reported cases of some 223% between 1995.  In 2004 over 100,000 cases alone were
reported by genitourinary clinics.  Chlamydia is currently the most commonly
reported sexually transmitted disease.  Infection rates appear to be highest
amongst young adults.  Recent surveys have shown that over 8% of young women
(under 20 years) attending GP clinics have Chlamydia.  The prevalence rises to
over 17% of young women attending genitourinary medicine clinics. It is thought
that 5% of the general population have the disease.

Commenting on the new product Michael Scorey, Chairman, said: "This new approved
test for Chlamydia is a major development for the company and presents us with a
very exciting sales and growth opportunity this financial year.  Our original
test continues to sell well - particularly over the Internet.  We will market
the new test primarily through pharmacies.  Already, our distributors have
presented the test to a number of pharmacies whose response to the product has
been both positive and encouraging.  The lower price point of #20 will open this
new sector to the company.  The Government has recently begun to target 16 to 25
year olds with a screening program initiative.  Our new test will have immediate
appeal to this group.  There is much to recommend the NHS screening program, but
I feel it will not able to meet the demand.  Time is of the essence for
treatment of this disease.  Our test is readily available, very discrete and
affordable."



                                    -Ends-

NOTES TO EDITORS

*  Personal Screening is an established supplier of health screening kits for
home use. It currently supplies kits to test for total and high density
cholesterol, prostate disorders, the menopause, bowel disorders, diabetes,
gonorrhoea, osteoporosis and chlamydia.


Contact


Personal Screening plc
Michael Scorey, Chairman                              01384 350 222
michaelscorey@perscreen.com


Binns & Co PR Ltd                                     020 7786 9600
Peter Binns                                           07768 392 582
Chris Steele                                          07979 604 687
chris.steele@binnspr.co.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRAAKKKBABKDFND